Literature DB >> 6149156

Interactions of agonists with peripheral alpha-adrenergic receptors.

R R Ruffolo.   

Abstract

The alpha adrenoceptors may be subdivided based on their anatomical distribution within the synapse. Presynaptic alpha adrenoceptors are generally of the alpha 2 subtype and modulate neurotransmitter liberation via a negative feedback mechanism. Postsynaptic alpha adrenoceptors are usually of the alpha 1 subtype and mediate the response of the effector organ. Although this anatomical subclassification is generally applicable, many exceptions are now known. A more useful classification of alpha-adrenoceptor subtypes is based on a pharmacological characterization in which selective agonists and antagonists are used. Two major classes of alpha-adrenoceptor agonists are known: the phenethylamines, which are structurally related to norepinephrine, and the imidazolines, which are structurally related to clonidine. A number of important differences between these two classes of agonists have been observed and have led to the conclusion that the phenethylamines and imidazolines interact differently with alpha adrenoceptors. Many developments have recently been made in regard to peripheral alpha adrenoceptors in the cardiovascular system. Postsynaptic alpha adrenoceptors in the vasculature represent a mixed population of alpha 1 and alpha 2 adrenoceptors. Both alpha-adrenoceptor subtypes mediate vasoconstriction, but appear to do so through different mechanisms. alpha 1 adrenoceptors also exist in the heart and mediate a positive inotropic response. Renal alpha 1 and alpha 2 adrenoceptors have been identified and subserve a variety of functions such as regulation of renal blood flow, gluconeogenesis, renin release, and sodium and water reabsorption.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149156

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  10 in total

1.  An evaluation of the alpha-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males.

Authors:  R F Schafers; H L Elliott; C A Howie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

2.  Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both alpha 1- and alpha 2-adrenoceptors.

Authors:  H Nielsen; F V Mortensen; M J Mulvany
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 3.  Synaptic control of motoneuronal excitability.

Authors:  J C Rekling; G D Funk; D A Bayliss; X W Dong; J L Feldman
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

4.  Vasoactive responses of a human cystic artery: adrenoceptor characterization.

Authors:  D G Wyse
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

5.  Modification of local anesthetic toxicity by vasoconstrictors.

Authors:  S E Taylor; R L Dorris
Journal:  Anesth Prog       Date:  1989 May-Jun

6.  A response to isoprenaline unrelated to alpha- and beta-adrenoceptor agonism.

Authors:  R A Bond; D E Clarke
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

7.  Alpha-adrenoceptor activity of arylalkylimidazoles is improved by alpha-methylation and impaired by alpha-hydroxylation.

Authors:  J M Savola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

8.  Prazosin, an alpha 1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat.

Authors:  C F Brosnan; E A Goldmuntz; W Cammer; S M Factor; B R Bloom; W T Norton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Effect of histamine on the airway smooth muscle of cats under control and inflammatory conditions.

Authors:  P Bánovcin; P Visnovský
Journal:  Agents Actions       Date:  1988-04

10.  Alpha 1- and alpha 2-adrenoreceptor actions of phentolamine and prazosin on breathing movements in fetal sheep in utero.

Authors:  D A Giussani; P J Moore; L Bennet; J A Spencer; M A Hanson
Journal:  J Physiol       Date:  1995-07-01       Impact factor: 5.182

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.